[Drugs under development for osteoporosis ].

Area of Science:

• Orthopedics and Bone Health
• Pharmacology
• Geriatric Medicine

Background:

• Osteoporosis significantly impacts bone health, characterized by reduced bone density and increased fracture risk.
• Affecting over 10 million individuals in Japan, osteoporosis poses a major public health challenge.
• Current treatments focus on maintaining bone homeostasis to prevent fragility fractures.

Purpose of the Study:

• To review the current development status of anti-osteoporotic medications.
• To provide an overview of established and emerging therapeutic strategies for osteoporosis.

Main Methods:

• Literature review of anti-osteoporotic drug development.
• Summary of existing anti-resorptive and anabolic drug classes.
• Discussion of novel drug targets, including osteoclast-specific therapies.

Main Results:

• Established anti-resorptive drugs (bisphosphonates, raloxifene) effectively increase bone mass and prevent fractures.
• Anabolic agents like parathyroid hormone are utilized for bone building.
• Newer therapies, including anti-RANKL drugs and cathepsin K inhibitors, are under development to target osteoclasts directly.

Conclusions:

• A range of anti-osteoporotic drugs are available and in development, targeting different mechanisms of bone remodeling.
• Continued research into novel drug targets promises improved management of osteoporosis.
• Effective therapeutic strategies are crucial for reducing the burden of osteoporotic fractures.